EGFR与HER-2在不同分子类型乳腺癌中的表达及其相关性分析

doi:10.3969/j.issn.1004-616x.2022.02.008

Abstract

Abstract: OBJECTIVE： To investigate expression and correlation of EGFR and HER-2 in different types of breast cancer tissues. METHODS：A retrospective analysis of 650 cases of breast cancer (600 cases of invasive ductal carcinomas， 50 cases of invasive lobular carcinoma) and 30 cases of fibroadenoma was conducted at the Surgery Treats in Handan Central Hospital from Jan. 2015 to Mar. 2020. Expression of EGFR and HER-2 were detected in 650 cases of breast cancers and 30 cases of fibroadenomas via routine detection of EGFR and HER-2 proteins by immunohistochemical method. χ² test and Spearman correlation analyses were used for statistical analysis of the data，and P<0.05 was considered statistically significant. RESULTS：The positive rate of EGFR expression in breast invasive ductal carcinoma was 48.7% which was significantly higher than that in invasive lobular carcinoma (24.0%) and fibroadenoma (16.7%) (P<0.01). The positive rate of HER- 2 expression in breast invasive ductal carcinoma was 27.8% which was significantly higher than that in invasive lobular carcinoma (8.0%) and fibroadenoma (6.7%) (P=0.002). In invasive ductal and lobular carcinomas of the breasts，the EGFR positive rate gradually increased with the increase of HER-2 score grade，and the EGFR positive rate was positively correlated with HER-2 score grade (r=1.000， P<0.05)， and the positive rate of EGFR was positively correlated with the expression of HER-2 (r=1.000，P<0.05). The positive rate of EGFR in HER-2 overexpression and TNBC was significantly higher than that in Luminal A and Luminal B， and Luminal B (HER-2 ⁺) than Luminal B (HER-2^-). CONCLUSION：The positive rates of EGFR and HER-2 were significantly increased in invasive cholangiocarcinoma of the breasts，and the positive rate of EGFR was positively correlated with the grade and positive rate of HER-2. EGFR was significantly elevated in HER-2-overexpressing and TNBC which would provide clues and evidence for targeted drug therapy for HER-2 positive breast cancers and triple negative breast carcinomas.

Key words: breast cancer, invasive ductal carcinoma, epidermal growth factor receptor, human epidermal growth factor receptor 2, immunohistochemisty

CLC Number:

R737.9

GUO Xiaojuan, WANG Jinxi, NIU Guangxu, TIAN Yunxiao. Expression and correlation analyses of EGFR and HER-2 in different types of breast cancers[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 119-123,148.

References

[1] World Health Organization. Global Cancer Observatory(GCO): Cancer Today[EB/OL]. [2020-04-01]. https://gco.iarc.fr.
[2] 张雪, 董晓平, 管雅喆, 等. 女性乳腺癌流行病学趋势及危险因素研究进展[J]. 肿瘤防治研究, 2021, 48(1): 87-92.
[3] JUTTEN B, ROUSCHOP K M A. EGFR signaling and autophagy dependence for growth, survival, and therapy resistance[J]. Cell Cycle, 2014, 13(1): 42-51.
[4] 杨伟斌, 刘志毅, 曹宽, 等. 表皮生长因子受体家族特点及与肿瘤关系的研究进展[J]. 现代肿瘤医学, 2019, 27(2): 346- 351.
[5] 詹琦, 周晟, 娄丽萍. EGFR, HER2和HER3在胆管癌中的表达及预后价值[J]. 实用肿瘤学杂志, 2019, 33(6): 491-496.
[6] 吕燕萍, 吴传城, 杨双凤, 等. 胃癌差异表达miRNA及其相关基因的单核苷酸多态性与胃癌预后的相关性研究[J]. 癌变· 畸变·突变, 2020, 32(5): 380-386.
[7] FENG K C, GUO Y L, DAI H R, et al. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer[J]. Sci China Life Sci, 2016, 59(5): 468- 479.
[8] 宋欣, 吕亚莉, 李向红. EGFR和Her-2蛋白表达及基因扩增的应用研究[J]. 诊断病理学杂志, 2014, 21(3): 175-178.
[9] 夏红强, 何建蓉. Ki-67、EGFR、HER-2和p53在乳腺癌中的表达及其相关性[J]. 临床肿瘤学杂志, 2011, 16(2): 139-143.
[10] ARAKI K, MIYOSHI Y. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer[J]. Breast Cancer, 2018, 25(4): 392-401.
[11] HEDNER C, BORG D, NODIN B, et al. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment[J]. J Clin Pathol, 2018, 71(5): 451-462.
[12] 汪中明, 周怀英, 吴华玲, 等. 表皮生长因子受体蛋白与临床病理特征对乳腺癌新辅助化疗效果和预后的影响[J]. 河北医药, 2020, 42(3): 325-329.
[13] 杨悦, 万义增, 陈素贤, 等. 结直肠癌组织中EGFR及HER-2的表达及临床意义[J]. 临床与实验病理学杂志, 2015, 31(6): 615-618.
[14] 向青林, 张伟. HER2、EGFR、VEGFR在胃印戒细胞癌中的表达及其临床意义[J]. 医学信息, 2020, 33(6): 87-89.
[15] 段海波, 胡倩, 林颖欣, 等. 曲妥珠单抗联合拉帕替尼及多西紫杉醇一线治疗HER-2阳性晚期乳腺癌的安全性和有效性[J]. 现代肿瘤医学, 2020, 28(18): 3159-3163.
[16] 郭艳, 张长庆. 靶向HER2/EGFR分子双特异性单链抗体的构建及其体内外抗乳腺癌的研究[J]. 检验医学与临床, 2018, 15(19): 2887-2891.
[17] ISHITHA G, MANIPADAM M T, BACKIANATHAN S, et al. Clinicopathological study of triple negative breast cancers[J]. J Clin Diagn Res, 2016, 10(9): EC05-EC09.
[18] 李星枝, 王舰梅, 肖秀丽, 等. GATA-3和 EGFR在乳腺癌中表达的相关性及其与分子亚型、临床病理资料的关系[J]. 川北医学院学报, 2021, 36(4): 414-418.
[19] 马阳, 吴娟, 纪晓坤, 等. 沉默表皮生长因子受体的表达对肺腺癌A549细胞自噬的影响[J]. 癌变·畸变·突变, 2019, 31(5): 347-351, 358.
[20] 李杰, 李诗, 李芳, 等. 三阴型乳腺癌中AR、SOX10、EGFR和PD-L1的表达及临床意义[J]. 临床与实验病理学杂志, 2021, 37(3): 344-347. resistance[J]. Cell Cycle, 2014, 13(1): 42-51.
[4] 杨伟斌, 刘志毅, 曹宽, 等. 表皮生长因子受体家族特点及与肿瘤关系的研究进展[J]. 现代肿瘤医学, 2019, 27(2): 346- 351.
[5] 詹琦, 周晟, 娄丽萍. EGFR, HER2和HER3在胆管癌中的表达及预后价值[J]. 实用肿瘤学杂志, 2019, 33(6): 491-496.

Expression and correlation analyses of EGFR and HER-2 in different types of breast cancers

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	XIN Yumeng, LIANG Huanxi, SUN Zhenxiao. Effectiveness of licorice and dried ginger decoction against mouse breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 88-92.
[2]	XIN Yumeng, LIANG Huanxi, YU Yuehua, SUN Zhenxiao. Network pharmacology and molecular docking mechanisms of licorice and dried ginger decoction against breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 7-13.
[3]	ZHAO Yan, SUN Zhenxiao. Metformin inhibitd proliferation and migration of human breast cancer cell in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 35-39.
[4]	FANG Yutong, ZHANG Qunchen, HONG Chaoqun, CHEN Chunfa, CHEN Jiongyu, ZHANG Rendong, WU Jundong. Mechanisms of miR-221 and miR-222 on expression of GATA3 and FOXA1 and their effects in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 435-441,460.
[5]	ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.
[6]	CHENG Bin, WANG Xinyu, SUN Yu, ZHANG Jiatai, DONG Shuying. Inhibition of metformin on phthalate-induced proliferation and migration of MCF-7 breast cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 197-202.
[7]	LUO Jiao, ZHANG Kunchi, ZHOU Li. Analysis of differentially expressed microRNAs between the triple negative breast cancer cell line MDA-MB-231 and its brain metastasis cell line [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 218-224.
[8]	LI Weiwei, ZHU Ying. Data mining analyses of expression and prognostic values of the MYB family in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 414-422.
[9]	CHEN Mianling, MA Shuoyi. Regulation of migration and invasion of triple-negative breast cancer cell MDA-MB-231 by miR-21 via targeting PDCD4 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(4): 292-297.
[10]	ZHANG Huijuan, HUANG Dayuan, ZHANG Jie, TANG Haiou, XIE Anxin, TAN Dunyong. Effects of SF1a-PRLR and ΔS2 SF1a-PRLR on proliferation and microRNA expressionin MCF-7 breast cancer cell [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 203-208.
[11]	SUN Quanwu, DU Xiaoping, HAO Jie, SHI Rong, LIU Bo, HUANG Haiyun. β1 integrin expression in breast cancer patients with pathological nipple discharge [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 368-372.
[12]	WANG Lan, ZHANG Yongdong, GUO Hongyun, WANG Tao, WANG Haitao, GUO Huan, YANG Suisheng, LI Xiaoqin, SU Haixiang. Relationships between XRCC3 polymorphisms and breast cancer in northern Chinese women [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 392-396,400.
[13]	DU Juan, HU Xiangyang, LIU Dan, HU Wei, CHEN Tao. Inhibitory effect of total alkaloids of Tougucao on bone metastasis of breast cancer cells in mice [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(6): 435-441.
[14]	XIAO Hongmei, PAN Tianqi, DONG Shunan, FU Lingmeng, WANG Shaokang, SUN Guiju. Menopausal status on risk for breast cancer from tea consumption: a meta-analysis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(5): 395-399.
[15]	JIANG Pengtao, HU Zhifang, GAO Xingchun, GUO Na, ZHANG Dian, JIANG Fengliang. Involvement of p53 in regulation of DNA damage-induced cell death in MDA-MB-231 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(5): 349-353.